11 recruiting, 5 active not recruiting, 4 completed, 4 terminated. 20 Phase 1, 13 Phase 2, 3 Not applicable.
Follow Recurrent Multiple Myeloma: new trials by email Literature Review of Recurrent Multiple Myeloma trials Research Report on Recurrent Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2027-06-01 | 2026-09-11 | |
| Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 80 | 2027-05-22 | 2026-10-20 |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma Allogeneic Defined Hematopoietic Stem Cells/Immune Cells, Busulfan, Filgrastim - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Not yet recruiting | University of California, Davis | 20 | 2026-09-01 | 2026-08-12 |
| Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Cytokine Release Syndrome, Recurrent Multiple Myeloma | Phase 2 | Recruiting | Naresh Bumma | 35 | 2026-07-17 | 2026-10-06 |
| A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma Biospecimen Collection, Cognitive Intervention, Electronic Health Record Review - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Multiple Myeloma | Not applicable | Recruiting | Ohio State University Comprehensive Cancer Center | 90 | 2026-04-28 | 2026-05-27 |
| Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2026-04-01 | 2026-05-15 | |
| Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma Linvoseltamab, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 30 | 2026-03-24 | 2026-09-16 |
| CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma Leukapheresis, Cyclophosphamide, Chimeric Antigen Receptor T cells (CAR-T) Targeting BCMA - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Suspended | Thomas Martin, MD | 30 | 2026-02-28 | 2026-06-11 |
| Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | Mayo Clinic | 44 | 2025-09-18 | 2026-08-26 |
| Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Older Patients Undergoing CAR-T Therapy for Relapsed or Refractory Multiple Myeloma Accelerometry, Aerobic Exercise, Biospecimen Collection - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Not applicable | Terminated | Mayo Clinic | 12 | 2025-08-18 | 2026-07-01 |
| Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease Mezigdomide, Carfilzomib, Dexamethasone - Extramedullary Disease in Multiple Myeloma, Recurrent Multiple Myeloma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 28 | 2025-05-01 | 2026-08-18 |
| Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma Iberdomide, Belantamab Mafodotin, Dexamethasone - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Suspended | Alliance for Clinical Trials in Oncology | 88 | 2025-04-23 | 2026-10-02 |
| SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Cxcr1/2 Inhibitor SX-682, Daratumumab and Recombinant Human Hyaluronidase, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | Roswell Park Cancer Institute | 15 | 2025-04-10 | 2026-08-13 |
| Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan - Recurrent Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 37 | 2025-03-18 | 2026-06-25 |
| ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Terminated | University of Washington | 1 | 2024-12-18 | 2025-07-29 |
| Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 26 | 2024-12-06 | 2026-10-22 |
| CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Withdrawn | Jonsson Comprehensive Cancer Center | 2024-03-28 | 2024-05-01 | |
| Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Cyclophosphamide - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Completed | Elvira Umyarova | 3 | 2024-03-05 | 2026-07-01 |
| Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma Belantamab Mafodotin, Biospecimen Collection, Bone Marrow Aspirate - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | Mayo Clinic | 62 | 2024-01-04 | 2026-07-14 |
Showing 20 of 31. Sign in to see all of them.
Multiple Myeloma (31) · Anemia (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Cytokine Release Syndrome (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Glioma (1) · Hematologic Neoplasms (1) · Leukemia, Plasma Cell (1) · Lung Neoplasms (1) · Lymphoma (1)
Blood Protein Disorders (31) · Cardiovascular Diseases (31) · Hematologic Diseases (31) · Hemic and Lymphatic Diseases (31) · Hemorrhagic Disorders (31) · Hemostatic Disorders (31) · Immune System Diseases (31) · Immunoproliferative Disorders (31) · Lymphoproliferative Disorders (31) · Neoplasms (31) · Neoplasms by Histologic Type (31) · Neoplasms, Plasma Cell (31) · Paraproteinemias (31) · Vascular Diseases (31) · Lymphatic Diseases (2)
Biopsy (18) · Magnetic Resonance Spectroscopy (16) · Specimen Handling (16) · Dexamethasone (15) · Calcium Dobesilate (14) · dexamethasone 21-phosphate (13) · dexamethasone acetate (13) · auricularum (12) · carfilzomib (10) · X-Rays (6) · Cyclophosphamide (5) · pomalidomide (5) · Phantoms, Imaging (4) · daratumumab (4) · fludarabine (4)
National Cancer Institute (NCI) (8) · Mayo Clinic (6) · Roswell Park Cancer Institute (3) · University of Washington (3) · Fred Hutchinson Cancer Center (2) · Abdullah Khan (1) · Alliance for Clinical Trials in Oncology (1) · Elvira Umyarova (1) · Jonsson Comprehensive Cancer Center (1) · Naresh Bumma (1) · Ohio State University Comprehensive Cancer Center (1) · Shanghai Theorion Pharmaceutical Co Ltd. (1) · Thomas Martin, MD (1) · University of California, Davis (1)
United States (30) · China (1) · Guam (1) · Puerto Rico (1)
Jens Hillengass, MD (2) · Rahul Banerjee, MD (2) · Abdullah M Khan, MBBS, MSc (1) · Anupama Kumar, MD (1) · Ashley E Rosko, MD (1) · Craig C Hofmeister (1) · Danai Dima, MD (1) · Diane K. Ehlers, PhD (1) · Elvira Umyarova, MD (1) · Hamza Hassan (1) · Hans C Lee (1) · Jian Hou, MD (1) · Keith T Flaherty (1) · Madhav Dhodapkar, MBBS (1) · Mehrdad Abedi (1)
PMID 26586415, PMID 32463741, PMID 33048619, PMID 35133871, PMID 35138919, PMID 36351402, PMID 37053535, PMID 37322121, PMID 37934000, PMID 38591867, PMID 39666929, PMID 39693587, PMID 39828738, PMID 39913886, PMID 40865033, PMID 41066729
U10CA180820 (3), UM1CA186691 (2), P01CA078902 (1), P30CA016058 (1), P30CA093373 (1), P50CA186781 (1), U01CA076576 (1), U24CA196172 (1), UM1CA186686 (1), UM1CA186688 (1), UM1CA186709 (1), UM1CA186712 (1)